Lupin Limited (LUPIN) — Announcement Announcement
📢 Key Event
Lupin receives tentative U.S. FDA approval for Revefenacin Inhalation Solution
💡 Investor Takeaway
This approval opens a $260.7 million U.S. COPD market opportunity for Lupin's generic launch.
Lupin announced it has received tentative U.S. FDA approval for its generic Revefenacin Inhalation Solution, a treatment for COPD that is bioequivalent to Mylan's Yupelri and targets a $260.7 million U.S. market. The approval positions Lupin to capture share in a significant respiratory drug segment and signals near-term revenue potential from U.S. launches.
📄 View Original Announcement (PDF)
About Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,04,071.47 Cr
P/E: 36.2
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.